Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Title: Intravitreal faricimab in diabetic macular edema with limited response to aflibercept
Purpose: The purpose of this investigator initiated study is to identify the effects of
intravitreal faricimab on recurrence-free treatment intervals and morphological features in
diabetic macular edema (DME) in which the Optical coherence tomography (OCT) guided treatment
interval failed to be extended to 6 weeks intervals in a treat and extend regimen using
aflibercept.
Objectives: The primary objective is to evaluate the proportion of patients with an increased
maximum treatment interval with intravitreal faricimab (compared to previous 4-week interval
under aflibercept) in an OCT guided treat and extend regimen at month 6 and 12. (for further
outcome measures see section Objectives)